Evidence map›Paper›PMID 38557174›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Deletion of the

Linnea Kristenson, Chiara Badami, Angelica Ljungberg, Erna Islamagic, Yarong Tian, Guojiang Xie, Brwa Ali Hussein, Silvia Pesce, Ka-Wei Tang, Fredrik B Thorén

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. TMEM16F phospholipid scramblase regulates tumorigenesis by modulating the tumor immune microenvironment.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Understanding and overcoming multidrug resistance in cancer.Nature reviews. Clinical oncology · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Linnea KristensonTumor Immunology (TIMM) Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg 413 90, Sweden.ORCID 0000-0003-0034-7875
Chiara BadamiTumor Immunology (TIMM) Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg 413 90, Sweden.ORCID 0009-0009-0973-7387
Angelica LjungbergTumor Immunology (TIMM) Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg 413 90, Sweden.ORCID 0009-0007-8727-7932
Erna IslamagicTumor Immunology (TIMM) Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg 413 90, Sweden.ORCID 0000-0002-1785-5035
Yarong TianTumor Immunology (TIMM) Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg 413 90, Sweden.
Guojiang XieTumor Immunology (TIMM) Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg 413 90, Sweden.
Brwa Ali HusseinTumor Immunology (TIMM) Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg 413 90, Sweden.ORCID 0000-0001-6657-9412
Silvia PesceTumor Immunology (TIMM) Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg 413 90, Sweden.ORCID 0000-0002-9798-4944
Ka-Wei TangTumor Immunology (TIMM) Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg 413 90, Sweden.
Fredrik B ThorénTumor Immunology (TIMM) Laboratory at Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg 413 90, Sweden.
University of Gothenburg · SESahlgrenska University Hospital · SEUniversity of Genoa · IT

Funding

Cancerfonden (Swedish Cancer Society) 19-0449Fondazione Umberto Veronesi (Umberto Veronesi Foundation) 2018-1914Stiftelsen Assar Gabrielssons Fond (AG Fond) FB18-35 FB19-62 FB20-75 FB21-76 FB22-32Stiftelserna Wilhelm och Martina Lundgrens (Wilhelm and Martina Lundgren Foundation) 2019-3167 2023-SA-4183Vetenskapsrådet (VR) 2020-02783
6 · The paper itself

Abstract

Natural killer (NK) cell immunotherapy has gained attention as a promising strategy for treatment of various malignancies. In this study, we used a genome-wide CRISPR screen to identify genes that provide protection or susceptibility to NK cell cytotoxicity. The screen confirmed the role of several genes in NK cell regulation, such as genes involved in interferon-γ signaling and antigen presentation, as well as genes encoding the NK cell receptor ligands B7-H6 and CD58. Notably, the gene

Indexed as

Hepatitis A Virus Cellular Receptor 2Killer Cells, NaturalLeukemiaLymphomaCell MembraneHumansInterferon-gammaMembrane ProteinsReceptors, Natural Killer CellHepatitis A Virus Cellular Receptor 2Interferon-gammaMembrane ProteinsReceptors, Natural Killer CellTMEM30a protein, humanCRISPR screennatural killer cellsphosphatidylserineTIM-3TMEM30A

Identifiers

PMID38557174
PMCPMC11009675
OpenAlexW4393381241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.